Literature DB >> 11372729

Wilms' tumor gene WT1: its oncogenic function and clinical application.

H Sugiyama1.   

Abstract

The Wilms' tumor gene WT1 is a gene responsible for the childhood renal tumor. Wilms' tumor, and is defined as a tumor suppressor gene. However, the wild-type WT1 gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin, and thus, WT1 messenger RNA provides a novel tumor marker for detection of minimal residual disease of leukemias and for monitoring disease progression of myelodysplastic syndromes. The WT1 gene exerts an oncogenic function rather than a tumor-suppressor gene function in solid tumors as well as leukemias, and the WT1 gene product is an attractive tumor antigen capable of eliciting cytotoxic T lymphocytes against WT1-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372729     DOI: 10.1007/bf02981935

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  71 in total

1.  Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.

Authors:  M Carapeti; J M Goldman; N C Cross
Journal:  Eur J Haematol       Date:  1997-05       Impact factor: 2.997

2.  Abnormal expression of the Wilms' tumor gene WT1 in juvenile chronic myeloid leukemia and infantile monosomy 7 syndrome.

Authors:  M Sako; H Ogawa; J Okamura; H Tamaki; T Nakahata; T Kishimoto; H Sugiyama
Journal:  Leuk Res       Date:  1998-10       Impact factor: 3.156

Review 3.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Mutation analysis of the WT1 gene in sporadic childhood leukaemia.

Authors:  E Algar; D Blackburn; T Kromykh; G Taylor; P Smith
Journal:  Leukemia       Date:  1997-01       Impact factor: 11.528

5.  Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript.

Authors:  E M Algar; M T Kenney; L A Simms; S I Smith; Y Kida; P J Smith
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

6.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

7.  Molecular mechanisms possibly affecting WT1 function in human ovarian tumors.

Authors:  A Viel; F Giannini; E Capozzi; V Canzonieri; C Scarabelli; A Gloghini; M Boiocchi
Journal:  Int J Cancer       Date:  1994-05-15       Impact factor: 7.396

8.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

9.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  30 in total

1.  Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer.

Authors:  Xu Lu; Jingwei Liu; Peilin Cui; Tao Liu; Chunmei Piao; Xianghong Xu; Qike Zhang; Man Xiao; Xuesong Liu; Yue Wang; Lin Yang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

3.  Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.

Authors:  Caroline Woehlecke; Susan Wittig; Clemens Arndt; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-20       Impact factor: 4.553

4.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

Review 5.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

6.  Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.

Authors:  Lili Xiang; Jiahe Zhou; Weiying Gu; Rong Wang; Jiang Wei; Guoqiang Qiu; Jiannong Cen; Xiaobao Xie; Zixing Chen
Journal:  Oncol Lett       Date:  2015-12-23       Impact factor: 2.967

Review 7.  Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone.

Authors:  Tsutomu Shichishima; Hideyoshi Noji
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

8.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.

Authors:  Adnan Jaigirdar; Steven A Rosenberg; Maria Parkhurst
Journal:  J Immunother       Date:  2016-04       Impact factor: 4.456

10.  Identification of mouse helper epitopes for WT1-specific CD4+ T cells.

Authors:  Hiroko Nakajima; Jun Nakata; Kanako Imafuku; Hiromu Hayashibara; Kazuki Isokawa; Keiko Udaka; Fumihiro Fujiki; Soyoko Morimoto; Kana Hasegawa; Naoki Hosen; Yoshiko Hashii; Sumiyuki Nishida; Akihiro Tsuboi; Yoshihiro Oka; Yusuke Oji; Shinji Sogo; Haruo Sugiyama
Journal:  Cancer Immunol Immunother       Date:  2021-07-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.